 The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of 56 in February this year before a large sell-off in FGEN stock, especially after the company disclosed that safety analyses from a late-stage study of Roxadustat. 